Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.

Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.

Eli Lilly is a leader in diabetes and obesity care, but it's also making progress elsewhere. Johnson & Johnson has a robust underlying business, and a rare and ongoing dividend streak.

Ford's dividend is high-yield, and unique thanks to family ownership. Altria Group is transitioning to smokeless tobacco, but its dividend remains a top option.

The Nasdaq Composite shed almost 1,400 points in a three-day stretch, which decisively pushed this growth-oriented index into correction territory. Heightened volatility on Wall Street is no reason for long-term investors to retreat to the sideline.

Dividends have played a significant role in the total returns of equity investments. The practice of consistently increasing dividends can be seen in the S&P 500 Dividend Aristocrats.

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT) The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN) SPRING HOUSE, Pa., Aug. 7, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results from the Phase 2 open-label UNITY study of nipocalimab for the treatment of alloimmunizeda pregnant individuals at risk of early onset severe (EOS) HDFN have been published in The New England Journal of Medicine (NEJM).

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Abbott Labs is a proven wealth builder at a fair price. Johnson & Johnson's a safe buy despite its ongoing litigation.

“Dividend Aristocrats

Dividend-paying stocks are ideal for outperforming the market or generating passive income. Finding dividend growth stocks, companies that have shown the ability and willingness to raise their distributions over time, providing consistent and growing income to investors, are even more valuable, particularly in this current market.

In a week where fear, uncertainty, and widespread selling swept the market, three stocks stood out for their resilience: Johnson & Johnson NYSE: JNJ, Coca-Cola NYSE: KO, and Procter & Gamble NYSE: PG.